Conversely, the upregulation of ASCT2 occurs in many cancers such as triple-negative breast cancer (Kim et al., 2013; van Geldermalsen et al., 2016), melanoma (Wang et al., 2014) and prostate cancer (Wang et al., 2013), and can correlate with poor prognosis, shown in studies of hepatocellular carcinoma (Namikawa et al., 2014; Sun et al., 2016) and non-small cell lung cancer (Shimizu et al., 2014; Yazawa et al., 2015). Here, SLC1A5 is linked to melanoma.